Dopamine D1 Receptors

Overall, our findings suggest that inhibition of the SHH signaling pathway is a potential therapeutic strategy for glioblastoma, and the combination of NVP-LDE-225 with FasL or TRAIL can sensitize GICs that are resistant to death receptor agonists

Overall, our findings suggest that inhibition of the SHH signaling pathway is a potential therapeutic strategy for glioblastoma, and the combination of NVP-LDE-225 with FasL

Share